Global Transarterial Chemoembolization (TACE) Market Trends, Opportunities, Top Company Players 2027

celinaredden

90
views

Global Transarterial Chemoembolization (TACE) Market Trends, Opportunities, Top Company Players 2027

Transarterial Chemoembolization (TACE) Market is expected to cross USD 2777.22 Million by 2025 at a CAGR of 8.57%.

Transarterial Chemoembolization (TACE) Market Research Report: By Procedure Type (Conventional TACE, DEB-TACE), Indication (Unresectable HCC, Early-Stage HCC), Product Type (Chemotherapeutic Agents, Radiotherapeutic Agents, Drug-eluting Particles), End-User (Hospitals & Clinics, Cancer Research Centers) - Forecast to 2027

GET FREE SAMPLE COPY @ https://www.marketresearchfuture.com/sample_request/8564

Transarterial Chemoembolization (TACE) Market Forecast

Transarterial Chemoembolization (TACE) Market is expected to cross USD 2777.22 Million by 2025 at a CAGR of 8.57%.

Transarterial Chemoembolization (TACE) Market Key Players

Advaxis Inc. (US)
Baxter (US)
Bellicum Pharmaceuticals, Inc. (US)
Boston Scientific Corporation (US)
Cook (US)
Hikma Pharmaceuticals PLC (UK)
Isofol Medical AB (Sweden)
Nippon Kayaku Co., Ltd. (Japan)
Novartis (Switzerland)
Pfizer (US)
Sirtex SIR-Spheres Pty Ltd. (Australia)
Spectrum Pharmaceuticals, Inc. (US)
Jiangsu Hengrui Medicine Co., Ltd. (China)

Segmentation

By Procedure Type

Conventional TACE: Conventional TACE dominated the Transarterial chemoembolization (TACE) market as it is one of the oldest procedures used in HCC cases. Conventional TACE involves the infusion of chemotherapeutic drugs blended with lipiodol and embolic agents into the cancer-feeding artery

DEB-TACE: This segment is expected to witness the fastest growth. DEB-TACE allows higher concentrations of drugs to the target tumor and lower systemic concentrations, compared with conventional TACE

By Indication

Unresectable HCC: TACE is a major treatment modality for unresectable HCC. The liver tumor which is not eligible for resection therapy given the extent of disease is considered as unresectable HCC

Early-Stage HCC: In case of early-stage HCC, TACE is recommended if resection or local ablation is not feasible

By Product Type

Chemotherapeutic Agents: Held the largest market share in 2018. Doxorubicin, cisplatin, and mitomycin are most commonly used in the TACE procedure. Doxorubicin is the most widely used chemotherapeutic agent for TACE of HCC. The dose of doxorubicin generally ranges from 30 to 75 mg/m2

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.